Cancer gene therapy using plasmid DNA: safety evaluation in rodents and non-human primates

Area of Science:

• Biotechnology
• Gene Therapy
• Immunology

Background:

• Plasmid DNA-lipid complexes are investigated for in vivo gene delivery.
• VCL-1005 is a novel complex containing human MHC class I genes (HLA-B7 and beta 2m) formulated with DMRIE/DOPE.
• Assessing the safety of such vectors is crucial before clinical application.

Purpose of the Study:

• To evaluate the safety and potential toxicity of the plasmid DNA-lipid complex VCL-1005.
• To determine the effects of repeated systemic and intrahepatic administration in animal models.
• To support the potential use of VCL-1005 in cancer gene therapy trials.

Main Methods:

• Conducted Good Laboratory Practice (GLP) safety studies in mice and cynomolgus monkeys.
• Administered VCL-1005 via repeated intravenous and intrahepatic injections at various doses.
• Monitored clinical chemistry, hematology, liver enzymes, and histopathology.

Main Results:

• In mice, repeated intravenous injections of VCL-1005 (up to 10 micrograms) showed only incidental effects on clinical chemistry and hematology, with no organ pathology.
• Intrahepatic injections in mice did not cause significant liver histopathology or enzyme alterations.
• In cynomolgus monkeys, a cumulative dose of 720 micrograms of DNA resulted in no adverse effects on clinical chemistry, hematology, or organ pathology.

Conclusions:

• Systemic administration of VCL-1005 did not induce significant toxicity or pathological immune responses in tested animals.
• The plasmid DNA-lipid complex VCL-1005 appears safe for in vivo delivery of recombinant DNA.
• These findings support the potential application of VCL-1005 in cancer gene therapy.